BIO17506-T1

Autophagy modulation for the treatment of obesity

Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvationinduced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.


Keywords : -
Patent Application number : PCT/EP2018/075286
Patent Application date : 2018-09-19
Multidisciplinary field : Fibrosis
Technology/Engineering : -
Technological Platform : -
Rare disease : -
Second indication : -
Inventors : José Manuel BRAVO-SAN
Guido KROEMER
Publications : -

Related offers


The 10 Last viewed

You haven't seen any form yet.